2nd International Rare Diseases Research Consortium (IRDiRC) conference is scheduled for November 7 - 9, 2014, in Shenzhen, China. The conference, co-organized by the BGI, is gathering stakeholders active in the field of rare disease from across the globe, with the aim to foster greater international collaborations involving Chinese researchers and clinicians.

Four exciting parallel tracks are organized over two conference days:

  • Diagnostics
  • Interdisciplinary-Technologies
  • Therapies
  • Education

An additional training course day dedicated to the enrichment of knowledge and scientific endeavors in rare diseases research.

It provides unmissable opportunity to network with different rare disease communities from Europe, North and South America, Africa, and Asia-Pacific. This conference creates the one of the largest stage in rare diseases field and aims to gather around 600 prominent participants, active in the areas of rare diseases including birth defects, neurological disorders, metabology, immunology, ophthalmology, auxology, genetic diseases, medical genetic, genetic consultation, and pharmaceuticals, as well as sample alliance and hospitals, pharmaceutical companies, patient organizations, non-governmental organizations (NGOs) from around the world, supported by more than 40 domestic and international media.

The IRDiRC brings together researchers and organizations investing in rare diseases research to achieve two main objectives: deliver 200 new therapies for rare diseases, and mean to diagnose most rare diseases, by the year 2020. The inaugural IRDiRC conference held in Dublin, Ireland, on 16-17 April 2013, gathered over 400 stakeholders from around the world.

Key Features:

  • Big platforms: access to big data and samples platforms, current discoveries, and advanced technologies.
  • Face-to-face meeting: a matchmaking workshop to facilitate collaborations between clinicians and scientists
  • Education and training: boosting training, learning, and networking as fundamental sources for new therapies

Speakers:

  • Karen Aiach, Founding President/CEO, Lysogene
  • Ségolène Aymé, Coordinator/Emeritus Director of Research, IRDiRC
  • Seng Cheng, Head of R&D, Rare Diseases, Genzyme (Sanofi)
  • Yann Le Cam, CEO, EURORDIS.

A list of additional Speakers is available here.

The IRDiRC program is available here.

To register please access the IRDiRC website.

For more information, please email irdirc.info@genomics.cn either in English or in Chinese.